Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
Expanded Access of Imvotamab (IGM-2323) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial.
Relapsed/Refractory Non-Hodgkin Lymphomas
BIOLOGICAL: IGM2323
Expanded Access of Imvotamab (IGM-2323) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial.